Todd Harrison

Part 2 of our interview with Todd Harrison, co-chair of the FDA practice group at Venable LLP covers preclusion's structural gaps: no defined end point, no tracking registry, and a push for mandatory drug-sponsor engagement.

Todd Harrison, co-chair of the FDA practice group at Venable LLP, details the Dietary Supplement Innovation Act's language, its unintended consequences, and what industry stakeholders should watch for.

In the second part of this interview, Todd Harrison, Co-Chair of the FDA Group at Venable LLP, discusses how the FDA and the industry handle novel ingredients in functional foods.

In the first part of this interview, Todd Harrison, Co-Chair of the FDA Group at Venable LLP, shares insights into regulatory methods, GRAS notices, and nutrition facts labeling surrounding the lawsuit against David Protein.